Back to top

Tale of the Tape

Zacks Equity Research

Arena Pharmaceuticals, Inc. Enters Oversold Territory
October 18, 2013


Trades from $3

Arena Pharmaceuticals, Inc.’s (ARNA - Analyst Report) share price has entered into oversold territory with an RSI value of 28.73. The Zacks Consensus Estimate on Arena Pharmaceuticals, Inc.’s earnings for the full year period has loss by 0.01 cents over the past two months to $-0.14 per share. Currently, Arena Pharmaceuticals, Inc. is a Zacks #2 Rank (“Buy”), suggesting that now might be a good time to get in on (ARNA - Analyst Report) after its recent drop.